Navigation Links
Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Date:9/10/2007

well as statements regarding the Company's future plans, objectives, performance, revenues, growth, profits, operating expenses or the Company's underlying assumptions. The words "may", "would", "could", "will", "likely", "expect," "anticipate," "intend", "plan", "forecast", "project", "estimate" and "believe" or other similar words and phrases are intended to identify forward-looking statements or information. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the value and use of data to be produced in the Phase 1 trial; the timing of announcing data from the Phase 1 trial; the launching of a Phase 2 clinical trial in CIN patients; the possibility of a second Phase 2 trial in HIV-positive CIN patients; the design of the Phase 1 trial; and the collection and use of immunological data to indicate efficacy of the compound.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials and the possibility that the results
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 Spartan Bioscience announced ... RX CYP2C19 System . It detects CYP2C19 genetic mutations ... swab. , The Spartan RX CYP2C19 System is the ... been approved in Canada. Due to the system’s ease ... be used by healthcare professionals such as doctors, nurses, ...
(Date:10/30/2014)... October 30, 2014 Avure Technologies celebrates a ... the newest member of its fleet of high volume High ... an anniversary as we return to PackExpo this year, which ... in Las Vegas,” said Jeff Williams, CEO at Avure. “Sales ... we’re pleased to be meeting the challenges of market demand ...
(Date:10/30/2014)... CARLSBAD, Calif. , Oct. 30, 2014 Isis ... antisense therapeutics, today announced that management will present a company ... 2014 at 8:30 a.m. ET in Boston, MA. ... will be available on the "Investors & Media" section of ... available on the Isis website within 48 hours and will ...
(Date:10/30/2014)... RIDGE, N.J. , Oct. 30, 2014  Regado ... that it will hold a conference call and live ... a.m. EST to discuss its third quarter 2014 financial ... the conference call by dialing (888) 347-1165 for domestic ... call will be webcast live under the investor relations ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Regado Biosciences to Provide Third Quarter 2014 Financial Results 2
... HOBOKEN, N.J. , Aug. 2 Octapharma USA ... Grants Program is the Rush Hemophilia & Thrombophilia Center at ... pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care ... ...
... CLEVELAND , Aug. 2 DATATRAK ... focused on global eClinical solutions for the clinical trials ... selected DATATRAK,s eClinical™ platform for a cardiovascular clinical study ... . Reaping the benefits of a unified platform, DAIICHI ...
... enough. Now imagine 15,000 of them. A Northwestern ... 15,000 identical skylines with tiny beams of light using ... Details of the new method, which could do for ... and information transfer, will be published Aug. 1 by ...
Cached Biology Technology:Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 2Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 3Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 4Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 5Octapharma Grants Program Awards First Research Grant to Rush University Medical Center 6DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study 2DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study 3DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical™ for Pan-European Systolic Hypertension Study 415,000 beams of light 215,000 beams of light 3
(Date:10/29/2014)... household and industrial products are in the environment – ... of them, scientists have yet to determine whether they ... toward doing that by estimating which substances people are ... in the ACS journal Environmental Science & Technology ... the risks to human health of any given substance ...
(Date:10/29/2014)... Mich. – As bodies decompose, their types and ... clues they provide could mean the difference between ... Michigan State University is using a more than ... Detroit death-scene investigators examine these changing populations. The ... geographical location of death, gender, race, socioeconomic relations ...
(Date:10/29/2014)... new research potential of the Barcode of Life ... the Biodiversity Data Journal (BDJ) ... and imported these into a human-readable text developed in ... Data were used to study the species distributions of ... subfamily. , BOLD is originally designed to support the ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... a type of contaminant in the atmosphere, considered very ... and visibility. Chemist Ms Ainhoa Inza studied the presence ... the Basque Country (CAV-EAE); concretely, the type known as ... micras in diameter. Amongst other things, the researcher compared ...
... Rochester Institute of Technology has been awarded a ... Standards and Technology to assist in construction of ... university,s Golisano Institute for Sustainability. The building will ... transfer, education and outreach and provide a state-of-the-art ...
... University of Wellington, New Zealand, crouched low to the ground and ... plant cushion, then sat back waiting to see if something would ... have thought so, but Pufal was trying to find potential plant ... Although the ability to move is typically thought to ...
Cached Biology News:Thesis studies atmospheric PM contaminant in the Basque Autonomous Community 2RIT receives federal grant to construct new sustainability research facility 2RIT receives federal grant to construct new sustainability research facility 3RIT receives federal grant to construct new sustainability research facility 4Plants that move: How a New Zealand species disperses seeds in a high alpine, wet environment 2Plants that move: How a New Zealand species disperses seeds in a high alpine, wet environment 3
The pCDF Expression System 1 plus Competent Cells contains 10 µg of pET-45b(+) DNA. pET-45b carries an N-terminal His•Tag ® coding sequence that is cleavable with enterokinase as well...
Nucleobindin 1 [NUCB1]...
Request Info...
... cells (HSC) are well-characterized tissue-specific stem cells ... responsible for the life-long maintenance of the ... reside in adult bone marrow where hematopoiesis ... be found in cord blood, fetal liver, ...
Biology Products: